US drug maker Eagle Pharmaceuticals listed on NASDAQ in 2014. It delayed its 3Q23 results after identifying problems with returns and pricing for its cancer drug, followed by management departures and further reporting delays. Accounts audited in July 2025 confirmed premature revenue recognition and other errors, reducing retained earnings at the end of 2022 from US$111.5m to US$94.7m. These corrections establish accounting misstatements, but do not establish deliberate fraud.

The information on this page has been compiled from publicly available sources. GMT Research Limited has not verified the information and does not warrant its accuracy. Any claims made or views expressed are not necessarily those of GMT Research Limited.